XML 38 R93.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Subsequent Events (Details) - Subsequent Event
$ in Millions
1 Months Ended
Jan. 31, 2020
USD ($)
ADSs  
Subsequent events  
Equity Method Investment, Ownership Percentage 25.00%
Equity Method Investment, Aggregate Cost $ 150.0
Incyte  
Subsequent events  
Percentage of development cost associated with global and US trials 55.00%
MorphoSys AG  
Subsequent events  
Percentage of development cost associated with global and US trials 45.00%
Upfront payment agreed to pay $ 750.0
MorphoSys AG | Development and Regulatory Milestones | Maximum  
Subsequent events  
Developmental, regulatory and commercial milestones 740.0
MorphoSys AG | Commercialization Milestones | Maximum  
Subsequent events  
Developmental, regulatory and commercial milestones $ 315.0